Abiomed, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Abiomed, Inc. (ABMD) develops, manufactures, and markets medical devices that assist or replace the pumping function of the failing heart and provide circulatory and oxygenation support; its core products include the Impella heart pump platform with models such as Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5, and Impella RP, which feature integrated motors, sensors, and optical technology for improved pump positioning and heart assessment; Impella SmartAssist and Impella Connect platforms for remote monitoring; the OXY-1 System for portable respiratory assistance; and technologies in development like Impella ECP for high-risk percutaneous coronary intervention, Impella XR Sheath, Impella BTR, and preCARDIA for acute heart failure. Founded in 1981 and headquartered in Danvers, Massachusetts, the company operates globally with facilities in the United States, Germany, and Japan, serving healthcare professionals in catheterization labs, cardiac surgery suites, and intensive care units for patients with acute heart failure, cardiogenic shock, and respiratory failure. Abiomed functions as a standalone business within Johnson & Johnson's MedTech segment following its acquisition by Johnson & Johnson, completed on December 22, 2022; recent developments include U.S. FDA expansion of Impella indications to pediatric patients in December 2024, positive pivotal study results for Impella ECP demonstrating safety and efficacy in October 2024, and presentations of long-term survival data and new guidelines supporting Impella use at TCT 2025 in October 2025.
Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.
IoMT Wearable Devices Patent Landscape Report and Forecasts, 2017-2023 & 2024-2032 Featuring Veniam, Advanced Neuromodulation Systems, Bionet Sonar, and Abiomed
US FDA classifies recall of Abiomed's blood pumps as most serious
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
Warren Buffett Loves These Stocks. Should You Buy Them Before 2023?
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
First Patients in the World Treated with Impella RP Flex with SmartAssist
Eleven Stocks Turned $10,000 To $261,421 In 11 Months
Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed
Is Johnson & Johnson's Purchase of Abiomed Good for Investors?
Beat the Dow Jones With This Unstoppable Dividend Stock
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ABIOMED, Inc. Buyout
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCO, ABMD, BNFT
ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc.
Why Abiomed Stock Skyrocketed Today
Abiomed Shares Pop 50% on Johnson & Johnson Buyout
Abiomed, Inc. (ABMD) Q2 2023 Earnings Call Transcript